Tenecteplase vs standard care for large vessel stroke 4.5-24 hours
Treatments studied
Part of Brain & nervous system, Heart & circulation clinical trials.
This trial tests if a clot-busting drug called tenecteplase can improve outcomes for people with a large vessel stroke when treatment starts 4.5 to 24 hours after symptoms began, and when a mechanical clot removal procedure (EVT) is not available. You would receive tenecteplase or standard medical care to see which works better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You had a stroke caused by a blocked large artery in the brain (ICA, M1, or dominant M2) and it has been 4.5 to 24 hours since you were last seen well
- Your stroke symptoms are moderate to severe (NIHSS score 6–25)
- You had good function before the stroke (mRS score 0–2) and brain imaging shows a large salvageable area (ASPECTS ≥7)
- You do not have access to mechanical clot removal (EVT) at this time
- You do not have recent major bleeding, history of brain bleed, current blood thinner use, or other conditions that increase bleeding risk
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a clot-busting drug called tenecteplase for people who had a stroke affecting the back part of the brain (posterior circulation). It may be an option if you can get treatment between 4.5 and 24 hours after symptoms started.
This trial tests a clot-dissolving medicine called tenecteplase for people who had a stroke more than 4.5 hours ago. It may help you recover if given later than usual.
This trial tests a clot-busting drug called tenecteplase given directly into the brain artery for people having a moderate stroke caused by a blockage in a medium-sized blood vessel. The goal is to see if it helps improve recovery when given within 24 hours of stroke symptoms starting.
This trial tests a new medication called rhTNK-tPA for treating acute ischemic stroke (a clot in the brain) up to 24 hours after symptom onset. The study uses simplified imaging to determine eligibility and aims to help patients recover better outcomes.
This trial tests a clot-busting drug called tenecteplase, given directly into the blocked artery, for people who have had a stroke caused by a medium-sized brain vessel blockage within the last 24 hours. It aims to see if this treatment is safe and effective in improving recovery.
This trial is testing whether a second dose of a clot-busting drug called tenecteplase can help people who are having a stroke and didn't get better after the first dose. The goal is to see if the extra dose is safe and effective.
Hear when a new Acute Ischemic Stroke trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.